Christine Willgoos

Christine Willgoos litigates patent actions on behalf of pharmaceutical and biotechnology companies, leading trial and appellate teams in Hatch-Waxman and biologic drug litigation, often involving blockbuster drugs. She represents biotechnology companies, including advising on biosimilar litigation. Christine is an accomplished courtroom advocate with significant experience, including trials and appeals, preliminary injunctions, and Markman hearings. She has handled cases in genetics, molecular biology, biochemistry and drug development, including those concerning biologic drugs, recombinant DNA vectors, cancer drugs, antidepressant drugs and dermatologic drugs. Her work extends across other industries as well, including medical devices, semiconductors, telecommunications and electronics.

Among her most notable work, Christine secured a preliminary injunction and trial victory for the plaintiff, the holder of the patent for the innovator drug, in Hatch-Waxman litigation. She currently represents clients in cases concerning immunoassay technology, cancer drugs and multiple sclerosis drugs.

In addition to litigation, Christine counsels clients in business and legal matters relating to patent portfolios, including antitrust, patent prosecution, life cycle management and regulatory issues.

Experience

Representing a pharmaceutical company in Hatch-Waxman litigation concerning a breakthrough, blockbuster cancer drug.
Representing a pharmaceutical company with respect to combination drugs to treat HIV/AIDS.
Represented a medical diagnostics company in patent litigation concerning next generation sequencing.

Represented a biotechnology company in patent litigation regarding immunoassay technology.
Represented a biotechnology company in patent litigation concerning the client’s humanized monoclonal antibody drug and vector systems for expression of polypeptides.
Represented a biotechnology company in a patent infringement suit concerning the client’s humanized monoclonal antibody drug and humanized antibody technology.
Represented a biotechnology company in a patent infringement suit concerning the client’s humanized monoclonal antibody drug and immune system complement activation system.
Represented a plaintiff in Hatch-Waxman litigation concerning an anti-inflammatory drug, obtaining a preliminary injunction precluding launch of a generic drug prior to trial and prevailing at trial, a decision that was affirmed by the Federal Circuit.
Represented plaintiffs in trial and appellate courts in a declaratory judgment suit concerning a blockbuster antidepressant drug.
Represented plaintiffs in litigation concerning the clients’ blockbuster antidepressant drug, obtaining a judgment in favor of the clients and securing an affirmance by the Federal Circuit.

Credentials

Education

J.D., cum laude, Boston University School of Law, 2001
- G. Joseph Tauro Scholar
- Paul J. Liacos Scholar
- American Journal of Law and Medicine, Staff Editor
Master of Forensic Science, Forensic Molecular Biology, George Washington University, 1997
B.S., Biochemistry, State University of New York at Geneseo, 1995

Bar Admissions

New York, 2002

Court Admissions

U.S.C.A., Federal Circuit
U.S.D.C., Eastern District of New York
U.S.D.C., Southern District of New York
U.S. Patent & Trademark Office

Professional Affiliations

New York City Bar Association, Science and Law Committee
New York Intellectual Property Law Association, Programs Committee
New Jersey Intellectual Property Law Association